Syntis Bio logo

Syntis Bio Funding & Investors

Milton, MA

Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability.

syntis.bio

Total Amount Raised: $53,372,180

Syntis Bio Funding Rounds

  • Series A

    $33,000,000

    Series A Investors

    Cerberus Capital Management
    Apollo Labs
    W.R. Berkley
    Touchdown Ventures
    Portal Innovations
    Woori Venture Partners
    Safar Partners
    Bold Capital Partners
    Colorcon Ventures
    Mansueto Investments

  • Grant

    $5,000,000

    Grant Investors

    National Institutes of Health (NIH)

  • Seed

    $15,372,179

    Seed Investors

    Portal Innovations
    Colorcon Ventures
    Touchdown Ventures
    Bold Capital Partners
    Safar Partners
Funding info provided by Diffbot.